The 3 best performing ASX shares of the week of 5 December 2022

Marc Kennis Marc Kennis, December 12, 2022

The 3 best performing ASX shares in the week of 5 December 2022

 

The 3 best performing ASX shares of the week starting 5 December 2022 were Tombador Iron (ASX:TI1), up 38.1%, Macarthur Minerals (ASX:MIO), up 25%, and Cardiex (ASX:CDX), up 22.2%.

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

 

1. Tombador Iron (ASX:TI1)

Industry: Resources

Our top 3 best performing ASX shares kicks off with Tombador Iron (ASX:TI1), which owns 100% of the fully permitted Tombador Iron Ore mine located in Bahia State Brazil. Tombador commenced production of premium-grade lump and fines hematite iron ore in May 2021 from a low-capex open-pit mining operation.

Market Cap: $62m

12 month high / low: $0.019 – $0.055

 

Tombador Iron

 

 

2. Macarthur Minerals (ASX:MIO)

Industry: Resources

Macarthur Minerals (ASX:MIO) is an iron ore development, gold and lithium exploration company that is focused on bringing to production its 100% owned Western Australia iron ore projects.

Market Cap: $33m

12 month high / low: $0.125 – $0.64

 

Macarthur Minerals

 

 

3. Cardiex (ASX:CDX)

Industry: Healthcare

Cardiex Limited (ASX:CDX) rounds out our top 3 best performing ASX shares this week. CDX is an ASX listed public company with operations in medical technology, wearable devices and telehealth, providing digital and device-based solutions for large-scale population health disorders with significant market scale. Its current focus is cardiovascular disease (CVD) and heart health.

Market Cap: $49m

12 month high / low: $0.25 – $0.72

 

Cardiex

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years

If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…

Cann Group

Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017

Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian…

CET1 ratio

CET1 ratio: If you invest in ASX bank stocks, here’s why it is an important metric to know

In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it…